Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Fournier's co-marketing agreement with Abbott for the lipid-lowering product will remain unchanged following Solvay's €1.3 bil. acquisition of the French company. Solvay will build a new cardio-metabolic division from Fournier, to be headquartered in Paris.
You may also be interested in...
First Horizon’s Triglide Could Have Compliance Benefit Over Other Fenofibrate Products
The novel fenofibrate formulation uses SkyePharma’s solubilization technology. First Horizon sees a fit with its existing cardiovascular products Altoprev and Fortamet.
First Horizon’s Triglide Could Have Compliance Benefit Over Other Fenofibrate Products
The novel fenofibrate formulation uses SkyePharma’s solubilization technology. First Horizon sees a fit with its existing cardiovascular products Altoprev and Fortamet.
Reliant's Antara Launch Set For First Quarter, Omacor Will Be Later
The cholesterol products have the potential to transform the company by generating annual sales of $150 mil. each, CEO Ernest Mario says. Reliant is considering possible combinations for Omacor; options include Antara or a statin.